CXCR4 and ovarian carcinoma: AMD3100 (1 μg/ml), a well-documented CXCR4 antagonist, inhibited cell proliferation in the presence of SDF-1, and verified the function of the SDF-1/CXCR4 axis in the tested ovarian cancer cells.